At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Study Comparing Cabozantinib (NSC #761968) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma
In Brief
A Phase 2 clinical trial evaluating Cabozantinib S-malate, Laboratory Biomarker Analysis, and 1 other intervention for Clear Cell Renal Cell Carcinoma and 3 related conditions. Completed, enrolled 157 participants across 488 sites.
Detailed Summary
This randomized phase II trial studies how well cabozantinib-s-malate works compared to sunitinib malate in treating patients with previously untreated kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib-s-malate and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether cabozantinib-s-malate is more effective than sunitinib malate in treating patients with kidney cancer.
Study Details
Timeline
Interventions
Given PO
Correlative studies
Given PO